altretamine


Also found in: Wikipedia.

altretamine

 [al-tret´ah-mēn]
an antineoplastic agent used in the palliative treatment of ovarian carcinoma. It is structurally related to an alkylating agent but does not act as one; its exact mechanism is unknown. Administered orally.

altretamine

/al·tret·amine/ (al-tret´ah-mēn) an antineoplastic agent used in the palliative treatment of ovarian cancer.

altretamine

an antineoplastic agent.
indications It is used for the palliative treatment of recurrent, persistent ovarian cancer after induction therapy agent.
contraindications< Known hypersensitivity to this drug, severe bone marrow depression, severe neurological toxicity, and pregnancy prohibit its use.
adverse effects Among the more serious adverse reactions are hepatic toxicity, leukopenia, thrombocytopenia, and anemia.

altretamine

Hexalen Oncology An alkylating anticancer agent. See Chemotherapy.

altretamine

An anticancer drug used to treat advanced caner of the ovary.

altretamine (altret´əmēn´),

n brand name: Hexalen;
drug class: antineoplastic;
action: products of metabolism interact with tissue macromolecules, including DNA, which may be responsible for cytotoxicity;
uses: palliative treatment of recurrent, persistent ovarian cancer.

altretamine

an antineoplastic agent, similar to tretamine.
References in periodicals archive ?
Altretamine is currently used to treat ovarian cancer, but these results suggest that, like sulfasalazine, it could be used for bowel inflammation or rheumatoid arthritis too.
Table 132:Ovarian Cancer Therapeutics Market, Global, Altretamine, Incidence of Adverse Effects, 2011 315
The same study found that most plans covered the following drugs, with median copays ranging from $5-$40: lomustine, thioguanine, bexarotene, erlotinib, exemestane, anastrozole, megestrol acetate, tamoxifen, chlorambucil, procarbazine, altretamine, and others.
Similarly, the major marketed drugs after 1990 approved for ovarian cancer were Altretamine (Hexalen), Gemcitabine (Gemzar), Hycamtin (Topotecan hydrochloride) and Yondelis (trabectedin).
One compound, altretamine, is marketed in the United States under the name Hexalen(R) for the treatment of advanced ovarian cancer.
One compound, altretamine, is marketed under the name Hexalen in the United States for the treatment of ovarian cancer.